|01/09/18||GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)|
|Voxelotor is First Investigational Treatment for SCD to Receive Breakthrough Therapy Designation
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD). Voxelotor is being developed as a disease-modifying therapy for SCD and previously... |
|01/03/18||GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 7:30 a.m. Pacific Time.
The presentation and Q&A session will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section.
GBT is a clinical-stage biopharmaceutical company determined to discover, deve... |